Mor­phoSys chops back again, this time cut­ting pre­clin­i­cal ef­forts in late-stage push

Al­most ex­act­ly a year af­ter Mor­phoSys $MOR sig­naled a re­treat out of the ear­ly-stage pro­grams picked up in its $1.7 bil­lion Con­stel­la­tion buy­out and con­cen­trat­ed its work in Ger­many, the biotech is back with an­oth­er R&D re­trench­ment.

Mor­phoSys ex­ecs said Thurs­day morn­ing they would chop out their en­tire pre­clin­i­cal ef­fort in a cost-cut­ting move, lay­ing off 17% of its work­force — with­out spec­i­fy­ing the num­ber — and tight­en­ing its re­search lines around late- and mid-stage clin­i­cal work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER